FDA Reclassification of Rapid Antigen Flu Testing

 

FDA reclassification of rapid flu antigen testing

Please join Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), Professor and Vice Chair for Laboratory Medicine in the Department of Pathology and Laboratory Medicine, and Medical Director of Clinical Laboratories, Molecular Pathology Laboratory and Point-Care-Testing at the Medical University of South Carolina, as he shares his insight regarding the recent FDA reclassification of Rapid Antigen flu testing, and why it's an opportunity for lab leadership.

 

Previous Article
Cleveland Clinic Case Study: How One Pathologist Got C-Suite Buy-In for Digital Pathology
Cleveland Clinic Case Study: How One Pathologist Got C-Suite Buy-In for Digital Pathology

Next Article
5 Ways to Improve Diagnostic Services to Boost Care
5 Ways to Improve Diagnostic Services to Boost Care

Learn how labs can improve diagnostic services within ACOs, helping to drive down costs and secure better p...

×

LabLeaders.com has a new home. Tell us a bit about yourself.

First Name
Last Name
Mobile Phone Number
Thank you!
Error - something went wrong!